Nexentis secures U.S. trademark for MITOLINE™ platform, strengthening drug discovery IP, enabling mitochondrial modeling, advancing pipeline, and boosting investor confidence.
Nexentis Technologies Inc., a drug discovery company, recently announced that its wholly-owned subsidiary, MitoCareX Bio Ltd., has secured official U.S. trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™. This significant approval, announced on May 5, 2026, marks a crucial step in solidifying the intellectual property and distinct identity of Nexentis's innovative drug discovery engine.
The MITOLINE™ platform is a specialized sequence analysis and alignment algorithm. Its primary purpose is to prepare mitochondrial carrier proteins of the SLC25 family for reliable 3D homology modeling. This capability is vital as it addresses a central bottleneck in mitochondrial drug discovery: the prevalent lack of solved 3D structures for most human mitochondrial carriers. By systematically aligning and annotating key amino acid sequences and specific residues, MITOLINE™ facilitates the generation of robust 3D comparative models for target mitochondrial carriers using established structural modeling tools.
MitoCareX Bio Ltd. is focused on developing novel therapies for challenging conditions such as hard-to-treat cancers and inflammatory metabolic diseases. It achieves this by precisely targeting proteins within the mitochondrial SLC25 carrier family. Leveraging the capabilities of MITOLINE™, MitoCareX has developed a cloud-based discovery engine. This engine is instrumental in the rapid identification of novel small molecule scaffolds that hold potential for impacting these complex diseases. The platform underpins MitoCareX's precision oncology and inflammatory-metabolic pipeline, enabling the characterization of substrate translocation pathways and binding pockets as functional targeting sites for virtual screening and hit optimization.
David Palach, CEO of Nexentis Technologies, emphasized the strategic importance of this trademark registration, stating it is "an important step in strengthening the distinct identity of our discovery engine as we scale MitoCareX within Nexentis." He further noted that MITOLINE™ is viewed as a strategic asset that differentiates their approach to mitochondrial biology and supports their objective of building a diversified pipeline of first-in-class small molecule programs.
Economically, the announcement had a positive immediate impact, with Nexentis Technologies' shares rising 10% following the news. However, it's important to note that the company has faced financial headwinds, with its stock down 97% over the past year, indicating it is rapidly burning through cash despite maintaining more cash than debt on its balance sheet. Beyond drug discovery, Nexentis Technologies also diversifies its business by investing in European renewable energy assets through a "Ready to Build" (RTB) business model and holds approximately 98% control of Save Foods Ltd., a company specializing in post-harvest treatment technologies for fruits and vegetables. The approval of the MITOLINE™ trademark represents a significant industry-specific advancement by addressing a critical challenge in drug discovery, potentially accelerating the development of new treatments for a range of severe diseases.
